NCT02089256

Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Tartu · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The study investigates the effect of glucagon-like peptide receptor 1 agonist, liraglutide, on insulin secretion. Study hypothesis: the effect of liraglutide on insulin release may change after repeated administration. The effect of liraglutide on insulin release will be tested using graded glucose infusion test (GGIT) in healthy volunteers. GGIT will be performed without medication and repeated 12 hours after first dose of liraglutide and after 3 weeks of treatment with liraglutide.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Liraglutide	Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated. GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection).

Timeline

• Start date: 2014-06-01
• Primary completion: 2015-03-01
• Completion: 2015-03-01
• First posted: 2014-03-17
• Last updated: 2015-04-01

Locations

1 site across 1 country: Estonia